Are Wall Street Analysts Predicting Bristol-Myers Squibb Stock Will Climb or Sink?

Princeton, New Jersey-based Bristol-Myers Squibb Company (BMY) discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products. With a market cap of $87.2 billion, the company focuses on products and experimental therapies that address cancer, heart disease, HIV and AIDS, diabetes, rheumatoid arthritis, hepatitis, organ transplant rejection, and psychiatric disorders.

Shares of this biopharma giant have considerably underperformed the broader market over the past year. BMY has declined 18.9% over this time frame, while the broader S&P 500 Index ($SPX) has rallied nearly 18.1%. In 2025, BMY stock is down 24.7%, compared to the SPX’s 17.2% gains on a YTD basis.